


## PHARMACEUTICAL 2020

## Axsome Therapeutics Inc. Rank 82 of 358





## PHARMACEUTICAL 2020



## Axsome Therapeutics Inc. Rank 82 of 358

The relative strengths and weaknesses of Axsome Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Axsome Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 133% points. The greatest weakness of Axsome Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 19% points.

The company's Economic Capital Ratio, given in the ranking table, is 182%, being 146% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	220,379
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	24,495
Liabilities, Non-Current	17,333
Other Assets	140
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-1,100
Other Revenues	0
Property and Equipment	31
Research and Development	53,647
Selling, General and Administrative Expense	13,598

Output Variable	Value in 1000 USD
Assets	220,550
Liabilities	41,827
Expenses	67,245
Revenues	0
Stockholders Equity	178,722
Net Income	-68,345
Comprehensive Net Income	-68,345
Economic Capital Ratio	182%

